PubRank

Luiz Belardinelli

Author PubWeight™ 169.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004 4.13
2 Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol 2013 3.90
3 Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007 2.90
4 Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 2012 2.78
5 Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2010 2.76
6 Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007 2.64
7 Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006 2.56
8 Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008 2.49
9 Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 2006 2.21
10 An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 2008 2.09
11 Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010 2.04
12 Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 2011 2.02
13 Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004 1.94
14 Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 2006 1.94
15 Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004 1.88
16 Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol 2009 1.78
17 Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007 1.77
18 Reactive oxygen species-activated Ca/calmodulin kinase IIδ is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circ Res 2011 1.69
19 Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice. Am J Physiol Cell Physiol 2011 1.69
20 Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004 1.66
21 Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res 2002 1.64
22 A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging 2009 1.63
23 Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 2004 1.52
24 CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure. Cardiovasc Drugs Ther 2007 1.52
25 Deranged sodium to sudden death. J Physiol 2015 1.51
26 Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003 1.51
27 Pathophysiology and pharmacology of the cardiac "late sodium current.". Pharmacol Ther 2008 1.50
28 Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. JACC Cardiovasc Imaging 2009 1.48
29 A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol 2003 1.46
30 Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008 1.46
31 Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007 1.42
32 Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 2012 1.39
33 Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 2008 1.35
34 Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 2006 1.30
35 Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2005 1.28
36 Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010 1.27
37 An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther 2005 1.27
38 Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm 2007 1.27
39 Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol 2010 1.26
40 A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006 1.24
41 Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm 2009 1.23
42 Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 2006 1.19
43 Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure. J Physiol Sci 2010 1.18
44 Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004 1.17
45 Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One 2010 1.16
46 Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res 2007 1.15
47 Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol 2009 1.13
48 A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol 2006 1.10
49 Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin) 2008 1.09
50 Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol 2011 1.08
51 Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 2003 1.07
52 Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 2009 1.05
53 Rapid kinetic interactions of ranolazine with HERG K+ current. J Cardiovasc Pharmacol 2008 1.04
54 The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res 2013 1.03
55 Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart. Am J Physiol Heart Circ Physiol 2009 1.03
56 Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008 1.03
57 Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation 2011 1.03
58 Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol 2011 1.03
59 Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2009 1.02
60 Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 2007 1.02
61 The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease. FASEB J 2012 1.01
62 A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 2007 1.00
63 Ranolazine antagonizes the effects of increased late sodium current on intracellular calcium cycling in rat isolated intact heart. J Pharmacol Exp Ther 2009 0.99
64 Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci 2008 0.97
65 The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. J Cardiovasc Electrophysiol 2006 0.97
66 Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 2003 0.96
67 Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. J Mol Cell Cardiol 2013 0.96
68 Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 2010 0.95
69 Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical model. Am J Physiol Heart Circ Physiol 2011 0.94
70 Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther 2011 0.94
71 The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol 2014 0.93
72 Simulation and mechanistic investigation of the arrhythmogenic role of the late sodium current in human heart failure. PLoS One 2012 0.93
73 Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967. Heart Rhythm 2013 0.92
74 Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm 2008 0.92
75 Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF). Curr Top Med Chem 2004 0.92
76 Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol 2011 0.92
77 Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther 2003 0.91
78 Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther 2008 0.91
79 A slowly inactivating sodium current contributes to spontaneous diastolic depolarization of atrial myocytes. Am J Physiol Heart Circ Physiol 2009 0.91
80 GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther 2012 0.90
81 CrossTalk proposal: The late sodium current is an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction). J Physiol 2014 0.90
82 Calmodulin kinase II and protein kinase C mediate the effect of increased intracellular calcium to augment late sodium current in rabbit ventricular myocytes. Am J Physiol Cell Physiol 2011 0.89
83 Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine. Circ Arrhythm Electrophysiol 2012 0.89
84 LQTS mutation N1325S in cardiac sodium channel gene SCN5A causes cardiomyocyte apoptosis, cardiac fibrosis and contractile dysfunction in mice. Int J Cardiol 2009 0.89
85 Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model. Heart Rhythm 2010 0.88
86 Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries. Hypertension 2012 0.88
87 Na+ channel function, regulation, structure, trafficking and sequestration. J Physiol 2015 0.88
88 A1 adenosine receptor: role in diabetes and obesity. Handb Exp Pharmacol 2009 0.88
89 A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Am J Physiol Endocrinol Metab 2007 0.88
90 The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace 2012 0.87
91 Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol 2008 0.86
92 Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J 2009 0.86
93 Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Heart Rhythm 2012 0.86
94 Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. J Pharmacol Exp Ther 2011 0.86
95 Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther 2007 0.86
96 Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat. Am J Physiol Heart Circ Physiol 2013 0.85
97 Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2013 0.84
98 A novel partial fatty acid oxidation inhibitor decreases myocardial oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart. J Cardiovasc Pharmacol 2008 0.84
99 Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation 2009 0.84
100 The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction. J Pharmacol Exp Ther 2009 0.84
101 An apoptosis signal-regulating kinase 1 inhibitor reduces cardiomyocyte apoptosis and infarct size in a rat ischemia-reperfusion model. J Cardiovasc Pharmacol 2012 0.84
102 Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm 2010 0.84
103 Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation. Heart Rhythm 2013 0.83
104 Ranolazine block of human Na v 1.4 sodium channels and paramyotonia congenita mutants. Channels (Austin) 2011 0.83
105 Sinus node dysfunction in ATX-II-induced in-vitro murine model of long QT3 syndrome and rescue effect of ranolazine. Prog Biophys Mol Biol 2009 0.83
106 Reducing the late sodium current improves cardiac function during sodium pump inhibition by ouabain. J Pharmacol Exp Ther 2011 0.83
107 Ranolazine reduces neuronal excitability by interacting with inactivated states of brain sodium channels. Mol Pharmacol 2013 0.83
108 Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model. Circ Cardiovasc Interv 2011 0.83
109 A computational modelling approach combined with cellular electrophysiology data provides insights into the therapeutic benefit of targeting the late Na+ current. J Physiol 2015 0.82
110 Selective attenuation of isoproterenol-stimulated arrhythmic activity by a partial agonist of adenosine A1 receptor. Circulation 2002 0.82
111 New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia. J Card Fail 2012 0.82
112 Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation. Europace 2012 0.82
113 Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. Europace 2013 0.81
114 In silico assessment of drug safety in human heart applied to late sodium current blockers. Channels (Austin) 2014 0.81
115 Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation 2005 0.81
116 Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease. Am J Cardiol 2012 0.81
117 Protein kinase C and Ca(2+) -calmodulin-dependent protein kinase II mediate the enlarged reverse INCX induced by ouabain-increased late sodium current in rabbit ventricular myocytes. Exp Physiol 2015 0.81
118 Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. J Pharmacol Exp Ther 2008 0.81
119 Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits. Heart Rhythm 2012 0.81
120 The effect of ranolazine on the vasodilator-induced myocardial perfusion abnormality. J Nucl Cardiol 2011 0.81
121 Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. J Cardiovasc Pharmacol 2010 0.81
122 Dronedarone's inhibition of If current is the primary mechanism responsible for its bradycardic effect. J Cardiovasc Electrophysiol 2013 0.81
123 Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol 2007 0.81
124 Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine. Neuropharmacology 2012 0.80
125 Increased late sodium current in left atrial myocytes of rabbits with left ventricular hypertrophy: its role in the genesis of atrial arrhythmias. Am J Physiol Heart Circ Physiol 2010 0.80
126 Selective inhibition of the late sodium current has no adverse effect on electrophysiological or contractile function of the normal heart. J Cardiovasc Pharmacol 2014 0.80
127 Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol 2003 0.79
128 A temporal window of vulnerability for development of atrial fibrillation with advancing heart failure. Eur J Heart Fail 2014 0.79
129 Carbon monoxide effects on human ventricle action potential assessed by mathematical simulations. Front Physiol 2013 0.78
130 Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol 2013 0.78
131 N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside, an A1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats. J Pharmacol Exp Ther 2003 0.78
132 A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther 2006 0.78
133 Contribution of I(K,ADO) to the negative dromotropic effect of adenosine. Basic Res Cardiol 2002 0.77
134 Abnormal left ventricular relaxation in patients with long QT syndrome. Eur Heart J 2009 0.77
135 Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation. J Cardiovasc Electrophysiol 2014 0.77
136 Response to letter regarding article, "Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy". Circulation 2013 0.77
137 Age-dependent atrial remodeling induced by recombinant human interleukin-11: implications for atrial flutter/fibrillation. J Cardiovasc Pharmacol 2002 0.76
138 Ranolazine attenuates hypoxia- and hydrogen peroxide-induced increases in sodium channel late openings in ventricular myocytes. J Cardiovasc Pharmacol 2014 0.76
139 A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies. J Electrocardiol 2004 0.76
140 Does recombinant human interleukin-11 exert direct electrophysiologic effects on single human atrial myocytes? J Cardiovasc Pharmacol 2002 0.76
141 Selective action of metoprolol to attenuate regadenoson-induced tachycardia in conscious dogs. J Nucl Cardiol 2011 0.76
142 Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application. J Cardiovasc Pharmacol Ther 2009 0.76
143 The first second-generation adenosine drug enters the US market. Purinergic Signal 2008 0.75
144 Adenosine A₁ receptors do not play a major role in the regulation of lipogenic gene expression in hepatocytes. Eur J Pharmacol 2012 0.75
145 Tonic activity of the rat adipocyte A1-adenosine receptor. Br J Pharmacol 2002 0.75
146 Reply: In regard to the TERISA trial. J Am Coll Cardiol 2014 0.75
147 Rebuttal from Marc Pourrier, Sarah Williams, Donald McAfee, Luiz Belardinelli and David Fedida. J Physiol 2014 0.75
148 Potentiation of the negative dromotropic effect of adenosine by rapid heart rates: possible ionic mechanism. Basic Res Cardiol 2002 0.75
149 Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs. Eur J Pharmacol 2006 0.75
150 An example of the clinical selectivity of regadenoson for the A2a adenosine receptor. Am Heart Hosp J 2009 0.75
151 Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs. J Cardiovasc Pharmacol 2008 0.75
152 The Selective Late Sodium Current Inhibitor, Eleclazine, Unlike Amiodarone, Does Not Alter Defibrillation Threshold or Dominant Frequency of Ventricular Fibrillation. J Cardiovasc Pharmacol 2016 0.75